Free Daily Podcast Summary
The Doctor's Lounge: Daily Summaries Delivered
by The Doctor's Lounge
Where scalpels meet systems — and physicians say what they really think.Co-hosted by Dutch Rojas, Anthony DiGiorgio, DO, with Anish Koka, MD, Dan Choi, MD, & Sanat Dixit, MD — candid talks on healthcare policy, reform, physician autonomy & patient care.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 days ago1h 0m
The Cholesterol Debate: What the Keto Influencers Get Right (and Wrong)
Episode SummaryDr. Greg Katz, preventive cardiologist at NYU Langone and co-host of Beyond Journal Club, joins Anish to dissect the online cholesterol debate — specifically the claims made by science communicator Nick Norwitz, who has maintained an LDL over 500 mg/dL on a low-carb diet for seven years with no coronary plaque on CTA. Katz takes the data point seriously, walks through the limitations of coronary CTA and the flawed Keto CTA study, and explains why he still believes the burden of proof lies with those arguing diet-induced hypercholesterolemia is safe — while acknowledging where the cardiology establishment, including the new lipid guidelines, overcorrects. The conversation covers the accountability gap between clinicians and content creators, the failure of risk calculators in young patients, and what a well-designed trial to actually answer this question would look like.Chapter Markers00:00 Introduction — Dr. Greg Katz, NYU Langone cardiologist and Beyond Journal Club co-host01:40 What prompted the Substack: patients bringing in Nick Norwitz's content02:51 Who is Nick Norwitz — LDL of 500, low-carb diet, and the clean CTA05:38 Why Katz takes the question seriously but disagrees with the framing08:01 Familial hypercholesterolemia outliers: why some FH patients never have events10:05 The 50/50 problem — half of high-cholesterol patients have heart disease, half don't12:27 The Jody Plute story: homozygous FH, Thomas Starzl, and the portacaval shunt experiments17:37 Seven years of LDL 500 — is that long enough to know anything?18:21 Limitations of coronary CTA: what it can and can't see21:00 Why LDL gets put on a pedestal — and the cognitive dissonance of a diet that works22:05 The conflict of interest argument — and why it cuts both ways25:43 Burden of proof: mechanisms vs. outcomes data27:16 Statins and GLP-1 levels — why a mechanistic claim isn't the same as a clinical outcome31:38 Physician accountability vs. content creator accountability35:24 The Keto CTA study: what it found, what it didn't, and why the blinding controversy matters44:40 The new lipid guidelines: where they overcomplicate, where they overprescribe49:38 GLP-1 deficiency framing and the over-medicalization of well people55:54 Longevity medicine as "over-medicalization of well people"57:35 What a well-designed trial would actually look like1:00:01 Why the debate needs real research, not conjecture1:02:37 How Katz talks to statin-hesitant patients in clinic1:07:06 WrapCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod
- 5 days ago1h 5m
Gaming the System: LTACHs, Guidelines, and the Evidence Problem in American Medicine
Episode SummaryDr. Anil Makam — hospitalist, health services researcher at UCSF, and faculty at Zuckerberg San Francisco General — joins Drs. Koka and DiGiorgio for a wide-ranging conversation on the hidden mechanics of American healthcare. Makam breaks down long-term acute care hospitals (LTACHs): what they're for, how regional variation and perverse payment incentives have distorted their use, and what the 2016 site-neutral payment reforms actually did to the market. The conversation then shifts to Makam's research on clinical practice guidelines — specifically his 2018 study showing that the majority of ATS recommendations were grounded in low-quality evidence, many carrying strong designations anyway — and what that means for how clinicians should read and apply guidelines at the bedside. The episode closes on the FDA, indication creep, the limits of central planning in quality measurement, and what it actually means to be a good doctor in a system where you can't buy your way to better medicine.Chapter Markers00:00 Introduction — Dr. Anil Makam, UCSF hospitalist and health services researcher02:09 What is an LTACH? Origins, optimal use cases, and the vent-weaning niche08:09 How clinical practice led Makam to study LTACH utilization10:08 Geographic variation in LTACH use — decomposing what drives it14:16 Post-acute care economics: DRGs, payment systems, and perverse incentives19:11 Medicare Advantage denial rates and the two-tier access problem23:06 Market access vs. total closures: what the 100 LTACH closures actually mean24:04 Short-stay outlier rules and the "magical recovery" at the payment threshold26:07 Site-neutral payment reform and its effects on the LTACH market31:51 Moving to guidelines: evidence vs. recommendations33:38 The ATS guidelines study — what they found and the Twitter fallout39:34 How to practice when most of what we do lacks strong evidence43:38 Why guidelines are getting more confident on less evidence47:10 The generalist vs. specialist lens on evidence appraisal53:47 How do you measure what makes a doctor good?56:41 Three buckets of physician quality: technical, relational, cognitive01:00:06 Running a trial vs. appraising a trial — two different skills01:05:16 Indication creep and applying trial evidence to the wrong patients01:09:24 The FDA, Vinay Prasad, Marty McCary, and why reform failed01:13:45 Wrap-up and where to find MakamCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod
- 1 weeks ago53 min
The FDA, Unicure, and the Limits of Accelerated Approval
Episode SummaryAnish sits down with Adu, a med student and biotech investor, to work through the FDA's contested handling of Unicure's AMT-130 — a gene therapy for Huntington's disease delivered via stereotactic brain injection. They debate whether the underlying data justifies approval, why the agency's mid-course reversal has rattled the investor community, and what the Sarepta precedent should have taught everyone involved. The conversation broadens into a bigger question: given that desperate patient populations will always demand access to anything showing a signal, who is actually best positioned to make the call on whether a drug works — the FDA, the clinician, or the market?Chapter Markers00:00 FDA approval of AMT-130 and investor reaction01:16 Unmet need and the case for regulatory flexibility02:37 Sarepta, Duchenne's, and the cost of approving under pressure05:09 Accelerated approval done right: the Amylyx example09:14 Debating the AMT-130 data and the historical control problem13:53 Why stock price matters for trial funding17:20 How Prasad could have changed FDA culture differently19:37 The FDA's role from Kefauver-Harris to today22:26 Competing Huntington's therapies in the pipeline25:39 Prasad's tenure: what worked, what didn't28:27 Media coverage of the FDA and science journalismCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepod
- 1 weeks ago1h 7m
Salty About Medical Education: Bryan Carmody on What the System Gets Wrong
Episode SummaryPediatric nephrologist, medical educator, and "Sheriff of Sodium" Dr. Bryan Carmody joins Drs. Koka and DiGiorgio to challenge some of the most persistent narratives in American medicine. From the AAMC's physician shortage projections — which Carmody argues serve the interests of medical schools more than patients — to the mechanics of the residency match, application fever, ERAS pricing, and the largely unrealized promise of pass/fail Step 1, Carmody brings his characteristic data-driven skepticism to each topic. The conversation closes on what's arguably the most consequential question: what should residency selection actually be optimizing for, and why are program directors squandering the leverage they have to drive real change in undergraduate medical education?Chapter Markers00:00 Introduction02:02 How Carmody became the Sheriff of Sodium05:03 Why people keep getting medical education wrong07:46 The physician shortage: skepticism and incentives09:03 Rebutting the AAMC's 86,000-doctor shortfall projection11:17 Supply-induced demand and the limits of training more physicians17:06 Third-party payment, discretionary care, and the real drivers of access problems20:27 Who benefits from the physician shortage narrative26:36 GME funding: $45 billion, hospital incentives, and the case for or against it30:01 The Match explained: history, origins, and why it exists35:22 ERAS, NRMP, and the financial architecture of residency applications40:21 Preference signaling: what it is and why it's quietly capping application volume44:12 Is the Match a monopoly? The congressional report and the anti-competitive argument51:18 Step 1 pass/fail: the promise, the timing, and why it stalled55:43 What actually changed — and what didn't — after 202258:00 What program directors should be demanding — and aren't01:08:12 What we're not doing well in resident selection01:11:59 Using selection systems to elevate the quality of every applicant, win or lose01:18:45 The neurosurgery combineCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod
- 2 weeks ago1h 26m
Free Markets, Private Equity, and the Moral Case for Medicine
Episode SummaryJared Rhoads, founder of the Center for Modern Health and senior lecturer in health policy at the Dartmouth Institute, joins Drs. Koka and DiGiorgio for a wide-ranging conversation on the philosophical foundations of healthcare policy. Rhoads — an Objectivist in the tradition of Ayn Rand — argues that physicians have a right to pursue health, not a right to be given it, and walks through what that distinction means for real policy debates: FDA drug approval, prior authorization, the ban on physician-owned hospitals, private equity in medicine, and foreign-trained physician licensure. The episode is a rare attempt to make the moral case for free markets in medicine, not just the efficiency case.Chapter Markers00:00 Introduction and guest background01:52 What is the Center for Modern Health?04:25 Objectivism, Ayn Rand, and rational self-interest11:19 Healthcare as a private good vs. community good13:58 Policy mistakes made for edge cases16:58 You have a right to pursue health — not to be given it20:14 Does Medicare violate rights?22:47 Positive vs. negative rights in healthcare24:47 The FDA, drug approval, and the Prasad/McCary departures31:08 A two-tier FDA review proposal: private vs. public payers42:25 Breaking up Big Medicine — the Hawley-Warren bill49:43 Prior authorization: structural problem or reform target?55:22 High-deductible plans and why price consciousness hasn't taken hold57:43 Price transparency laws: do they actually work?01:02:49 Section 6001 and the de facto ban on physician-owned hospitals01:06:04 Stark Law, Medicare Advantage, and a possible reform path01:11:19 Private equity in medicine: where are the actual rights violations?01:19:02 Free markets and monopolies: the standard objection answered01:21:12 Foreign-trained physician licensure01:34:11 Immigration, physician workforce, and the battle of ideas01:37:40 Center for Modern Health summer fellowshipCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod
- 2 weeks ago1h 11m
George Tolis: TAVR, Broken Training, and What's Really Wrong With Cardiac Surgery.
Episode SummaryDr. George Tolis, section chief of coronary and general cardiac surgery at Brigham and Women's Hospital, joins Drs. Koka and DiGiorgio for a wide-ranging conversation on the state of cardiac surgery. He makes the case that TAVR — while genuinely transformative for the right patient — is being systematically applied too broadly, driven by industry incentive and the erosion of meaningful surgical consent. He discusses his collaboration with John Ioannidis that found no statistically significant mortality benefit for any new cardiac surgery technique introduced over the past 35 years, the paper's rejection by every major surgical journal, and what he paid out of pocket to make it open access. The conversation moves to the collapse of surgical training — fragmented pathways, work hour restrictions that leave residents unprepared for attending life, an academic promotion system that ignores teaching, and a culture that routes incompetent trainees around rather than out — and closes with a brief on Vasily Kolesov, the Soviet surgeon from Leningrad who performed the world's first documented coronary bypass years before Favaloro, and whose work was buried by the Cold War.Chapter Markers00:00 Introduction01:02 Air-cooled VWs, concert piano, and how Dr. Tolis got here02:40 TAVR: genuine breakthrough or being abused?08:02 Finding the TAVR threshold — and why informed consent is the real problem11:46 Collaborating with John Ioannidis: no mortality benefit for 35 years of new techniques20:02 Why the major surgical journals wouldn't touch the paper21:52 Minimally invasive surgery: minimal access vs. minimally invasive26:24 When do CABG survival curves diverge — and what does it mean?30:05 Surgeons signing off on TAVRs in young patients33:51 Health system economics and the heart team dynamic37:50 How to actually pick a good surgeon (ask the scrub nurses)40:36 Cardiac surgery training: the three pathways problem44:04 Work hour restrictions and the residency simulation gap51:16 General surgery is like MTV — they don't operate anymore53:21 A resident who finished training without ever applying a cross-clamp56:34 How to evaluate if a program actually trains59:27 Academic promotion has nothing to do with teaching01:01:33 Dr. Tolis's resident outcomes database and three papers nobody cared about01:05:32 The training timeline: finishing at 49, no runway left01:07:08 One-size-fits-all RRC rules for cardiac surgery and psychiatry01:09:16 Cardiac surgery as a disposition, not a therapy01:12:24 When ECMO becomes the final common path01:13:38 How you become nationally recognized without being a good surgeon01:17:16 Vasily Kolesov: the Soviet surgeon who did the first bypassCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod
- 3 weeks ago1h 16m
Center-Right in a White Coat: Pradeep Shanker on AI, Vaccines, and Medical Orthodoxy
Episode SummaryRadiologist, National Review senior contributor, and prominent center-right voice in medicine Pradeep Shanker joins Anish Koka and Anthony DiGiorgio for a wide-ranging conversation that covers AI's real (and overstated) role in radiology, the structural dysfunction of GME funding and physician immigration, what went wrong with COVID policy from both the left and right, the asymmetric treatment of physicians like Mary Bowden versus institutional failures like Aduhelm, and whether America is still a creedal nation. Pradeep and Anish agree on more than expected — and disagree sharply where it counts.Chapter Markers00:00 Introduction and guest background02:23 AI in radiology — where it actually helps07:42 Ground truth, image resolution, and the limits of AI diagnostics12:16 Should AI replace the Nighthawk radiologist?19:40 CMS reimbursement and AI — does it help or hurt?21:09 Physician immigration and the GME funding problem27:49 Supplier-induced demand and the third-party payment trap35:52 Why we're not building enough American medical schools39:23 Affirmative action in medical training47:41 How did we do on COVID?51:26 Depoliticizing the CDC and NIH54:09 Vaccine mandates — where Pradeep draws the line56:42 How do you rebuild trust in public health?1:02:30 Mary Bowden, Vinay Prasad, and dissent in medicine1:08:42 The Aduhelm asymmetry1:16:35 Is America a creedal nation?Co-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/7vE4aCMpVHnSGwuOHiGVLpApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1489323962YouTube: https://www.youtube.com/@TheDoctorsLounge
- May 3, 20261h 24m
The Surgeon Who Refused to Bow: Dr. Eithan Haim on Blowing the Whistle at Texas Children's
Episode SummaryDr. Eithan Haim, a general surgeon in the Dallas area, joins Anish to walk through the events that took him from chief resident at Baylor to facing four federal felony counts and up to 10 years in prison. While rotating at Texas Children's Hospital in 2022 and 2023, Haim learned that the hospital's pediatric gender medicine program — which TCH had publicly announced it was shutting down in March 2022 — was in fact still operating, with puberty blocker implants being placed in children as young as 11. He took redacted information to journalist Christopher Rufo, the story ran in May 2023, and Texas passed SB 14 within 24 hours. A month later, federal agents showed up at his door on the day of his graduation. Haim describes the three successive indictments, the discovery that lead prosecutor Tina Ansari's family had financial ties to Texas Children's, the de facto gag order, the agreement signed under duress, and the dismissal with prejudice on January 24, 2025 — two weeks before trial. The conversation closes on what every physician should take from his case: the power asymmetry of federal prosecution, the weaponization of HIPAA, and why Haim believes telling the truth, even at total personal cost, is the only thing that ultimately matters.Chapter Markers00:14 Introduction and overview of the case02:18 Spring 2022 at Texas Children's — the first red flags05:29 Rotating at TCH as a chief resident06:59 Awakening to what was happening on the floor09:14 The 11-year-old patient and the role of residents10:38 Why institutional channels weren't an option11:11 Cold-emailing journalists under a pseudonym14:12 Did he access patient records? The transplant indictment myth16:29 Where the records actually came from17:44 Talking it through with his wife — a federal prosecutor20:09 Mandatory reporting and the duty of physicians in a hospital22:36 The knock at the door on graduation day25:24 Going public in January 202428:26 "She'll bring it to trial even knowing she'll lose"30:09 The 2024 election and what was at stake31:41 Breaking down the four felony HIPAA counts36:32 Why the DOJ went all in38:37 Tina Ansari and the chain of command39:24 Selectively tailored evidence to the grand jury42:25 The arraignment — sitting beside drug traffickers and sex offenders44:09 Discovering the prosecutor's financial ties to TCH46:43 The de facto gag order and the descent into chaos50:09 The agreement signed under duress52:24 January 24, 2025 — the day of dismissal56:50 The civil suit and Elon Musk's involvement58:09 What this means for every physician in America1:01:16 What HIPAA enables and why it needs to change1:04:00 Privacy law versus mandatory reporting1:06:51 The banana republic problem — power and resources1:08:16 On Dostoevsky, legacy, and the calculus of telling the truth1:11:00 Would he have done it differently?1:12:43 Hypothetical: would the same standard apply to a left-leaning whistleblower?1:15:01 On Jay Bhattacharya, Fauci, Collins, and the question of justice1:21:00 Closing thoughts on courage, corruption, and the duty of physicians
About The Doctor's Lounge
Where scalpels meet systems — and physicians say what they really think.Co-hosted by Dutch Rojas, Anthony DiGiorgio, DO, with Anish Koka, MD, Dan Choi, MD, & Sanat Dixit, MD — candid talks on healthcare policy, reform, physician autonomy & patient care.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Doctor's Lounge in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Doctor's Lounge daily summary?
It's a free AI-powered email that summarizes new episodes of The Doctor's Lounge as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Doctor's Lounge podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Doctor's Lounge product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by The Doctor's Lounge.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Doctor's Lounge release new episodes?
The Doctor's Lounge publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Doctor's Lounge cover?
The Doctor's Lounge covers topics including Business, Entrepreneurship, Medicine, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Doctor's Lounge summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.